A082 Clinical Outcomes in Patients With Severe Tricuspid Regurgitation (TR)

TR is associated with increased mortality and morbidity [[1]Wang N. et al.Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis.European Heart Journal. 2018; 40: 476-484Crossref Scopus (122) Google Scholar]. Current guidelines suggest concomitant tricuspid valve surgery at the time of left sided valve surgery [[2]De Bonis M. et al.Surgical and interventional management of mitral valve regurgitation: a position statement from the European Society of Cardiology Working Groups on Cardiovascular Surgery and Valvular Heart Disease.European Heart Journal. 2015; 37: 133-139Crossref Scopus (57) Google Scholar]. However, most patients with severe TR are managed conservatively. This is a retrospective study to assess clinical outcomes of patients with severe TR. 9507 transthoracic echocardiograms performed on adult patients at Waikato Hospital from August 2018 - July 2019 were analysed for clinical and demographic data. 124 patients had severe TR, with secondary TR occurring in 94.4%(n=117). Baseline characteristics were as follows: Table 1. Baseline Characteristics. 22.6%(n=28) of patients died in the study period (14 during hospital admission and 11 within 3 months of discharge). Average length of hospitalisation was 14±12.4 days. 50.8%(n=63) were rehospitalised within the study period. 19.4%(n=24) had >2 admissions. 28.3%(n=35) underwent previous cardiac surgery. 0.8%(n=1) underwent tricuspid valve surgery. 58.1%(n=72) had right ventricular dysfunction. 12.1%(n=15) had hepatic congestion. Māori had higher pulmonary hypertension (p=0.03) and lower left ventricular ejection fraction (p=0.03). Despite significant morbidity and mortality, patients with severe TR are not offered definitive intervention. Māori patients are associated with higher predictors of mortality.